This is a powerful conviction signal from ATTO's largest shareholders. Traders should watch for an imminent press release — likely positive Phase 1/2 data, a partnership deal, or a buyout offer — given the coordinated nature and size of these buys. The $17.00 price level now serves as a strong support floor. Consider building a long position ahead of expected catalysts, with a stop below $15.50 (just under the cluster's average cost).
Price Chart
Executive Summary
Five major 10% owners, including Sanofi, Redmile, venBio, Frazier Life Sciences, and Goldman Sachs, collectively purchased $33.5M of ATTO stock at $17.00/share in a single-day cluster on August 6, 2026. This represents ~4.1% of the company's $823M market cap, a highly material insider buy signal that strongly suggests these sophisticated investors see significant near-term upside, likely tied to upcoming clinical catalysts or a potential partnership/buyout. The cluster's size and composition (all top-tier healthcare investors) make this one of the strongest insider buy signals possible for a biotech of this size.
Key Financial Metrics
Key Facts
- Five 10% owners (Sanofi, Redmile, venBio, Frazier Life Sciences, Goldman Sachs) bought a total of $33.5M in ATTO stock on August 6, 2026.
- All purchases were at $17.00/share, representing ~4.1% of ATTO's $823M market cap.
- This is a single-day cluster buy by the company's largest and most sophisticated investors, not routine insider diversification.
- The $33.5M total value is the largest insider buying cluster in ATTO's recent history, following $18.7M in buys over the prior 30 days.
- No insider sales were reported in this cluster — the net direction is 100% buying.
Financial Impact
$33.5M in open-market purchases by five 10% owners at $17.00/share, representing ~4.1% of ATTO's $823M market cap
Risk Factors
- The cluster could be a pre-arranged secondary purchase or part of a PIPE that was already disclosed, reducing its signaling value.
- ATTO is a pre-revenue biotech with no approved products — clinical trial failure or regulatory delay could erase value regardless of insider buying.
- The stock has declined ~18% over the past week (based on prior report performance), suggesting the cluster may be a 'value buy' by insiders rather than a near-term catalyst signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ATTO-1786672365605 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Sep 28, 2026 28d ago | Press Release | $18.16 | awaiting T+20 | — | $13.88 (−23.57%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $13.88 (−42.64%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $13.88 (−35.14%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $13.88 (−25.58%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $13.88 (−30.04%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $13.88 (−31.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers